Iliopsoas hematoma in patients with COVID-19 on low-molecular-weight heparin treatment

Patients with COVID-19 are at high risk of thromboembolic events; for this reason, the use of heparin is largely recommended but, in addition to thrombotic complications, bleeding is a significant cause of morbidity in patients with COVID-19. Idiopathic iliopsoas hematoma is a very rarely described...

Descripción completa

Detalles Bibliográficos
Autores principales: Sottilotta, Gianluca, Mangano, Carmelo, Basile, Rosa, Falcone, Carmela, Luise, Francesca, Megalizzi, Demetrio, Nicolò, Giovanna Maria, Oriana, Vincenzo, Piromalli, Angela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161851/
https://www.ncbi.nlm.nih.gov/pubmed/34104443
http://dx.doi.org/10.1177/2050313X211016991
Descripción
Sumario:Patients with COVID-19 are at high risk of thromboembolic events; for this reason, the use of heparin is largely recommended but, in addition to thrombotic complications, bleeding is a significant cause of morbidity in patients with COVID-19. Idiopathic iliopsoas hematoma is a very rarely described hemorrhagic complication in patients with COVID-19. We report here two cases of iliopsoas hematoma in male patients with COVID-19 and being treated with heparin.

Ejemplares similares